Furosemide for prevention of cyclophosphamide-associated sterile haemorrhagic cystitis in dogs receiving metronomic low-dose oral cyclophosphamide

2017 ◽  
Vol 15 (4) ◽  
pp. 1468-1478 ◽  
Author(s):  
L. Setyo ◽  
M. Ma ◽  
T. Bunn ◽  
K. Wyatt ◽  
P. Wang
Keyword(s):  
Low Dose ◽  
Oral Cyclophosphamide ◽  
Haemorrhagic Cystitis ◽  
Dose Oral

Low-dose oral cyclophosphamide-methotrexate maintenance (CMM) for receptor-negative early breast cancer (BC).

2015 ◽  
Vol 33 (15_suppl) ◽  
pp. 1002-1002 ◽  
Author(s):  
Marco Colleoni ◽  
Kathryn P. Gray ◽  
Shari I. Gelber ◽  
Istvan Lang ◽  
Beat J. K. Thurlimann ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Early Breast Cancer ◽  
Low Dose ◽  
Oral Cyclophosphamide ◽  
Dose Oral

scholarly journals Phase I-II study of everolimus and low-dose oral cyclophosphamide in patients with metastatic renal cell cancer

BMC Cancer ◽  
2011 ◽  
Vol 11 (1) ◽  
Author(s):  
Charlotte M Huijts ◽  
Saskia J Santegoets ◽  
Alfons J van den Eertwegh ◽  
Laura S Pijpers ◽  
John B Haanen ◽  
...  
Keyword(s):  
Phase I ◽  
Renal Cell Cancer ◽  
Renal Cell ◽  
Low Dose ◽  
Cell Cancer ◽  
Oral Cyclophosphamide ◽  
Metastatic Renal Cell Cancer ◽  
Dose Oral

A phase 1/2 study of lenalidomide with low-dose oral cyclophosphamide and low-dose dexamethasone (RdC) in AL amyloidosis

Blood ◽  
2012 ◽  
Vol 119 (23) ◽  
pp. 5384-5390 ◽  
Author(s):  
Efstathios Kastritis ◽  
Evangelos Terpos ◽  
Maria Roussou ◽  
Maria Gavriatopoulou ◽  
Constantinos Pamboukas ◽  
...  
Keyword(s):  
Light Chain ◽  
Low Dose ◽  
Phase 1 ◽  
Al Amyloidosis ◽  
Oral Cyclophosphamide ◽  
Phase 2 ◽  
Light Chain Amyloidosis ◽  
Intention To Treat ◽  
Oral Regimen ◽  
Dose Oral

Abstract In this phase 1/2 study, we explored the feasibility and activity of an oral regimen of lenalidomide with low-dose dexamethasone and low-dose oral cyclophosphamide (RdC) in patients with primary systemic light chain amyloidosis. RdC was given for up to 12 cycles in prespecified cohorts at escalated doses: 13 patients were treated in phase 1 and 24 in phase 2; 65% were previously untreated, and most had renal and/or cardiac involvement and elevated cardiac biomarkers. Lenalidomide 15 mg/d and cyclophosphamide 100 mg/d were further evaluated in phase 2. On intention to treat, 20 (55%) patients achieved a hematologic response, including 3 (8%) complete remissions. Hematologic responses were seen at all dose levels and in 4 of 5 patients who had received bortezomib previously. An organ response was recorded in 22% of patients on intention-to-treat and in 40% of patients who survived at least 6 months. The median time to progression was 10 months and the 2-year survival was 41%. Fatigue, nonneutropenic infections, and rash were the most common toxicities. The results of the present study show that RdC is an oral regimen with activity in primary systemic light chain amyloidosis and may be an additional treatment option, especially for patients with preserved organ function or for patients who cannot receive or who relapse after bortezomib. This study is registered at www.clinicaltrials.gov as NCT00981708.

scholarly journals Phase 1 study of everolimus and low-dose oral cyclophosphamide in patients with metastatic renal cell carcinoma

2018 ◽  
Vol 68 (2) ◽  
pp. 319-329 ◽  
Author(s):  
Charlotte M. Huijts ◽  
◽  
Inge M. Werter ◽  
Sinéad M. Lougheed ◽  
Ruben S. Goedegebuure ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Metastatic Renal Cell Carcinoma ◽  
Renal Cell ◽  
Low Dose ◽  
Phase 1 ◽  
Oral Cyclophosphamide ◽  
Phase 1 Study ◽  
Dose Oral

Bortezomib in combination with intermediate-dose dexamethasone and continuous low-dose oral cyclophosphamide for relapsed multiple myeloma

2007 ◽  
Vol 138 (3) ◽  
pp. 330-337 ◽  
Author(s):  
Martin Kropff ◽  
Guido Bisping ◽  
Elke Schuck ◽  
Peter Liebisch ◽  
Nicola Lang ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
Low Dose ◽  
Oral Cyclophosphamide ◽  
Dose Oral ◽  
Intermediate Dose

Bortezomib in Combination with High-Dose Dexamethasone and Continuous Low-Dose Oral Cyclophosphamide for Relapsed Multiple Myeloma.

Blood ◽  
2005 ◽  
Vol 106 (11) ◽  
pp. 2549-2549 ◽  
Author(s):  
Martin Kropff ◽  
Guido Bisping ◽  
Peter Liebisch ◽  
Orhan Sezer ◽  
Hermann Einsele ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
Low Dose ◽  
Response Rate ◽  
Single Agent ◽  
Median Number ◽  
High Dose ◽  
Oral Cyclophosphamide ◽  
Minor Response ◽  
Chromosome 13 ◽  
Dose Oral

Abstract Single agent bortezomib treatment yields ≥ partial responses (PR) in 24% of patients with relapsed, refractory multiple myeloma (MM) and 38% of patients who had received 1 – 3 previous therapies. Dexamethasone (DEX) adds to anti-myeloma activity of bortezomib. The present phase II trial was intitiated to study bortezomib combined with DEX and continuous low-dose oral cyclophosphamide (CY). 50 patients with advanced MM were scheduled to receive bortezomib 1.3 mg/m2 IV days 1, 4, 8, and 11 q 3 weeks for 8 cycles in combination with DEX 20 mg PO on the day of bortezomib injection and the day thereafter, and CY 50 mg PO daily; followed by 3 cycles bortezomib 1.3 mg/m2 IV days 1, 8, 15, and 22 q 5 weeks in combination with corresponding DEX and CY schedules. Patient characteristics included median age 63 years; B2M > 3,0 mg/L, 64%; CRP > 3,0 mg/L, 25%; deletion of chromosome 13, 46%; median number of prior regimens, 2 (range 1 – 9), and prior standard therapy > 12 mo, 94 %. 78% of patients had relapsed after high-dose melphalan. The EBMT criteria were used for definition of response. Five patients (10%) achieved a complete response, 33 (66%) a PR, and 6 (12%) a minor response (MR) resulting in an overall response rate (≥MR) of 88%. On an intention-to-treat basis, median event-free survival (EFS) with this combination was 10 months. After a median follow-up of 10 months, median overall survival has not been reached. Notably, chromosome 13 deletion was predictive of a favorable outcome (higher response rate, longer EFS) in this setting. The median number or treatment cycles given was 6. 56% of the patients terminated study treatment prematurely, mainly for disease progression (10%) or adverse events (34%). Grade 4 neutropenia during at least one treatment cycle occurred in one patient (2%), grade 4 thrombocytopenia in 17%; one thrombocytopenic bleeding. Grade 3/4 non-hematologic toxicities requiring dose or schedule modifications included infections (26%), peripheral neuropathy (25%), fatigue (15%), herpes zoster (13%), and cardiovascular events (11%). One patient succumbed to infection without predisposing neutropenia. Bortezomib in combination with DEX and CY appears to be a highly active regimen without increased toxicity compared to a single agent treatment with bortezomib. Maintenance treatment might be required for prolonged EFS.

Sign in / Sign up

Export Citation Format

Share Document